Genetic Technologies (US:GENE) — Company Overview, News & Financial Data
Genetic Technologies specializes in genetic testing, developing tools for predictive assessment of diseases like cancer.
GENEGenetic Technologies
Company profile
About Genetic Technologies
Genetic Technologies (ASX:GTG), (NASDAQ:GENE) specializes in the development and commercialization of genetic risk assessment technology. The company's innovative projects revolve around DNA genotyping and analysis, aiming to provide predictive testing and assessment tools for diseases such as cancer. By harnessing advancements in genomics, Genetic Technologies seeks to revolutionize personalized healthcare, enabling more precise, predictive, and preventative care strategies. Their objective is to become a key player in the genetic testing market, offering solutions that can significantly improve patient outcomes through early detection and personalized treatment plans.
Snapshot
Public USOwnership
1987Year founded
60Employees
Melbourne, AustraliaHead office
Loading Map...
Global footprint
Operations
All Locations
Melbourne, AU
Products and/or services of Genetic Technologies
- GeneType for Breast Cancer Risk Assessment, a genetic test providing personalized breast cancer risk.
- GeneType for Colorectal Cancer Risk Assessment, a test offering personalized colorectal cancer risk.
- GeneType for Cardiovascular Disease Risk Assessment, assessing individual risk for cardiovascular diseases.
- GeneType Multi-Test, combining assessments for several cancers and diseases into a single test.
- Consumer Initiated Testing (CIT) platform, enabling consumers to access genetic testing directly.
- GeneType for Type 2 Diabetes Risk Assessment, identifying individual risk for developing Type 2 Diabetes.
Genetic Technologies executive team
- Mr. Kevin CamilleriChief Executive Officer of EasyDNA
- Mr. Mark ZiirsenCFO & Company Secretary
- Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIAConsultant
- Dr. Erika Spaeth Ph.D.Director of Clinical & Scientific Affairs